Related Experiment Video
Updated: Mar 14, 2026
Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
Published on: June 27, 2025
The emerging role of immunotherapy in colorectal cancer
1Department of Internal Medicine, University of North Carolina Hospitals, Chapel Hill, North Carolina, USA ;
Abstract:
Modulation of the interaction between the immune system and the tumor microenvironment has long been a target of cancer research, including colorectal cancer (CRC). Approaches explored to date include vaccines (autologous, peptide, dendritic cell, viral and bacterial), cytokine therapy, toll-like receptors (TLRs), autologous cell therapy and checkpoint inhibition. Until recently these approaches have been shown to have only modest efficacy in reducing tumor burden. However, significant breakthroughs have been made, with the use of checkpoint inhibitors targeting programmed cell death protein-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T lymphocyte antigen-4 (CTLA-4). Immunotherapy now represents a possible avenue of curative treatment for those with chemo-otherwise refractory tumors. Success with this approach to immunotherapy has largely been confined to tumors with high mutational burdens such as melanoma, renal cell carcinoma (RCC) and non-small cell lung cancer. This observation led to the exploration and successful use of checkpoint inhibitors in those with mismatch repair colorectal cancer which have a relatively high mutational burden. Ongoing trials are focused on further exploring the use of checkpoint inhibitors in addition to investigating the various combinations of immunotherapeutic drugs.
Insights
Immunotherapy, particularly checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4, shows promise for refractory colorectal cancer (CRC). This approach is effective in mismatch repair deficient CRC due to its high mutational burden.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Modulating the immune system and tumor microenvironment is crucial in cancer research, including colorectal cancer (CRC).
- Previous immunotherapeutic approaches like vaccines and cytokine therapy had limited efficacy in reducing tumor burden.
- Significant advancements have been made with immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4.
Purpose of the Study:
- To review the advancements in immunotherapy for colorectal cancer.
- To highlight the role of immune checkpoint inhibitors in treating refractory CRC.
- To discuss the potential of immunotherapy as a curative treatment option.
Main Methods:
- Review of existing literature on cancer immunotherapy and colorectal cancer treatments.
- Analysis of the efficacy of various immunotherapeutic strategies, including checkpoint inhibitors.
- Exploration of the link between tumor mutational burden and immunotherapy response.
Main Results:
- Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 have shown significant breakthroughs.
- Immunotherapy offers a potential curative treatment for chemo-refractory tumors.
- Checkpoint inhibitors are effective in mismatch repair deficient colorectal cancer due to its high mutational burden.
Conclusions:
- Immunotherapy, especially checkpoint inhibitors, represents a promising treatment avenue for colorectal cancer.
- Further research and clinical trials are ongoing to explore combinations of immunotherapeutic drugs.
- The success in high mutational burden tumors like melanoma and RCC paved the way for CRC applications.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...